

Monika Warmuth-Metz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4092598/publications.pdf>

Version: 2024-02-01

46
papers

2,791
citations

236612

25
h-index

214527

47
g-index

47
all docs

47
docs citations

47
times ranked

3260
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial. <i>Neuro-Oncology</i> , 2022, 24, 127-137.	0.6	9
2	Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3ÅK27M Mutant Diffuse Midline Glioma. <i>Clinical Neuroradiology</i> , 2022, 32, 249-258.	1.0	8
3	MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial. <i>Radiology</i> , 2022, 304, 174-182.	3.6	12
4	European Society for Paediatric Oncology (SIOPE) MRI guidelines for imaging patients with central nervous system tumours. <i>Child's Nervous System</i> , 2021, 37, 2497-2508.	0.6	26
5	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. <i>Neuro-Oncology</i> , 2021, 23, 1012-1023.	0.6	19
6	High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): management strategies and results from the German LGG study group. <i>Neuro-Oncology</i> , 2021, 23, 1148-1162.	0.6	9
7	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. <i>Journal of Neuro-Oncology</i> , 2021, 155, 193-202.	1.4	6
8	Retrospective analysis on the consistency of MRI features with histological and molecular markers in diffuse intrinsic pontine glioma (DIPG). <i>Child's Nervous System</i> , 2020, 36, 697-704.	0.6	12
9	CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. <i>Acta Neuropathologica</i> , 2020, 140, 405-407.	3.9	30
10	Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low-grade glioma patientsâ€”Report from the German <sc>SIOPE</sc> LGG</sc> 2004 cohort. <i>International Journal of Cancer</i> , 2020, 147, 3471-3489.	2.3	19
11	Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 1856-1865.	3.2	10
12	Prognostic impact of distinct genetic entities in pediatric diffuse glioma <sc>WHO</sc>â€”grade <sc>II</sc>â€”Report from the German/Swiss <sc>SIOPE</sc> LGG</sc> 2004 cohort. <i>International Journal of Cancer</i> , 2020, 147, 2159-2175.	2.3	8
13	MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma. <i>Clinical Neuroradiology</i> , 2019, 29, 595-604.	1.0	26
14	Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort. <i>American Journal of Neuroradiology</i> , 2019, 40, 1811-1817.	1.2	9
15	GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS. <i>Neuro-Oncology</i> , 2019, 21, ii82-ii82.	0.6	2
16	SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma. <i>Klinische Padiatrie</i> , 2019, 231, 107-135.	0.2	52
17	Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. <i>American Journal of Neuroradiology</i> , 2019, 40, 568-575.	1.2	4
18	Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features â€”a retrospective analysis of the HIT ependymoma trial cohort. <i>Acta Neuropathologica Communications</i> , 2019, 7, 181.	2.4	21

#	ARTICLE	IF	CITATIONS
19	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. <i>Neuro-Oncology</i> , 2018, 20, 13-23.	0.6	74
20	Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. <i>Neuro-Oncology</i> , 2018, 20, 123-131.	0.6	184
21	Management of primary thalamic low-grade glioma in pediatric patients: results of the multicenter treatment studies HIT-LGG 1996 and SIOP-LGG 2004. <i>Neuro-Oncology Practice</i> , 2017, 4, 29-39.	1.0	12
22	A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors. <i>Nature Medicine</i> , 2017, 23, 1191-1202.	15.2	38
23	Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype. <i>American Journal of Neuroradiology</i> , 2017, 38, 1892-1898.	1.2	21
24	Multinodular and Vacuolating Neuronal Tumor of the Cerebrum: A New "Leave Me Alone" Lesion with a Characteristic Imaging Pattern. <i>American Journal of Neuroradiology</i> , 2017, 38, 1899-1904.	1.2	90
25	A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (>16 years) low grade glioma: A final report. <i>European Journal of Cancer</i> , 2017, 81, 206-225.	1.3	104
26	Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. <i>American Journal of Neuroradiology</i> , 2016, 37, 1581-1587.	1.2	31
27	Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. <i>Journal of Clinical Oncology</i> , 2016, 34, 4151-4160.	0.8	121
28	Primitive neuroectodermal tumors of the brainstem in children treated according to the HIT trials: clinical findings of a rare disease. <i>Journal of Neurosurgery: Pediatrics</i> , 2015, 15, 227-235.	0.8	16
29	Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes. <i>Neuro-Oncology</i> , 2015, 17, 1029-1038.	0.6	167
30	Strategies to improve the quality of survival for childhood brain tumour survivors. <i>European Journal of Paediatric Neurology</i> , 2015, 19, 619-639.	0.7	36
31	Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified. <i>Neuro-Oncology</i> , 2015, 17, 1157-1165.	0.6	33
32	Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. <i>Neuro-Oncology</i> , 2015, 17, 160-166.	0.6	124
33	Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: A report from the german multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG). <i>Pediatric Blood and Cancer</i> , 2014, 61, 457-463.	0.8	36
34	Treatment of Children With Central Nervous System Primitive Neuroectodermal Tumors/Pinealoblastomas in the Prospective Multicentric Trial HIT 2000 Using Hyperfractionated Radiation Therapy Followed by Maintenance Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 863-871.	0.4	39
35	Neuropsychological Outcome in Patients with Childhood Craniopharyngioma and Hypothalamic Involvement. <i>Journal of Pediatrics</i> , 2014, 164, 876-881.e4.	0.9	60
36	Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. <i>Neuro-Oncology</i> , 2013, 15, 224-234.	0.6	69

#	ARTICLE	IF	CITATIONS
37	Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. <i>Neuro-Oncology</i> , 2012, 14, 1265-1284.	0.6	213
38	Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. <i>Neuro-Oncology</i> , 2011, 13, 669-679.	0.6	149
39	Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006. <i>Journal of Neuro-Oncology</i> , 2011, 102, 459-469.	1.4	22
40	Recurrence in childhood medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 103, 705-711.	1.4	22
41	Impact of chemotherapy on disseminated low-grade glioma in children and adolescents: Report from the HIT-LGG 1996 trial. <i>Pediatric Blood and Cancer</i> , 2011, 56, 1046-1054.	0.8	47
42	Thalamic high-grade gliomas in children: a distinct clinical subset?. <i>Neuro-Oncology</i> , 2011, 13, 680-689.	0.6	64
43	Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT-91. <i>European Journal of Cancer</i> , 2009, 45, 1209-1217.	1.3	173
44	CT and MR imaging in atypical teratoid/rhabdoid tumors of the central nervous system. <i>Neuroradiology</i> , 2008, 50, 447-452.	1.1	96
45	Role of Radiotherapy in Supratentorial Primitive Neuroectodermal Tumor in Young Children: Results of the German HIT-SKK87 and HIT-SKK92 Trials. <i>Journal of Clinical Oncology</i> , 2006, 24, 1554-1560.	0.8	85
46	Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the german prospective randomized trial hit 91. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 269-279.	0.4	382